NCT00728598View on ClinicalTrials.gov

Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 1998

Primary Completion Date

December 31, 1998

Study Completion Date

December 31, 1998

Conditions
Proliferative Diabetic RetinopathyAngiogenesis
Trial Locations (1)

Unknown

The department of ophthalmology, National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT00728598 - Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis | Biotech Hunter | Biotech Hunter